

# CITATION REPORT

List of articles citing

## Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective

DOI: 10.1016/j.clinthera.2016.10.008  
Clinical Therapeutics, 2017, 39, 1012-1025.

**Source:** <https://exaly.com/paper-pdf/67657937/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2017</b> , 17, 109-119	2.2	9
12	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. <i>BioMed Research International</i> , <b>2017</b> , 2017, 9257930	3	0
11	Traditional medicinal plants used for the treatment of diabetes in the Sudan: A review. <i>African Journal of Pharmacy and Pharmacology</i> , <b>2018</b> , 12, 27-40	0.5	7
10	Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 143, 88-100	7.4	28
9	Phlorizin Exerts Direct Protective Effects on Palmitic Acid (PA)-Induced Endothelial Dysfunction by Activating the PI3K/AKT/eNOS Signaling Pathway and Increasing the Levels of Nitric Oxide (NO). <i>Medical Science Monitor Basic Research</i> , <b>2018</b> , 24, 1-9	3.2	27
8	Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial. <i>Coronary Artery Disease</i> , <b>2020</b> , 31, 306-314	1.4	12
7	Enhancement of glucose homeostasis through the PI3K/Akt signaling pathway by dietary with Murrill in STZ-induced diabetic rats. <i>Food Science and Nutrition</i> , <b>2020</b> , 8, 1104-1114	3.2	4
6	Nocturnal Hypoglycemia in Type 2 Diabetes. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , <b>2018</b> , 25, 99-103	0.2	1
5	Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Journal of Obesity and Metabolic Syndrome</i> , <b>2019</b> , 28, 254-261	4.4	8
4	Efficacy of Liraglutide in clinical practice: Single centre experience. <i>Pakistan Journal of Medical Sciences</i> , <b>2020</b> , 36, 432-437	2	2
3	Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients. <i>Cureus</i> , <b>2020</b> , 12, e9937	1.2	1
2	Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. <i>American Health and Drug Benefits</i> , <b>2017</b> , 10, 178-188	1.7	52
1	Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS). <b>2022</b> ,		0